GSK, RSV
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new hope.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody concentrations (immune response to Shingrix) and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination.
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.
GSK makes Brooke Shields the star of shingles vaccination push
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and up about the power that comes from aging and how shingles threatens their health.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
GSK falls Thursday, underperforms market
GSK PLC GSK shares slipped 1.84% to £15.75 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.91% to 8,328.72. Supported ...
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
BioSpace3d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
GSK falls Tuesday, underperforms market
Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
pharmaphorum12h
ICER mulls GSK COPD drugs ahead of next Medicare negotiation
The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...